What You Should Know
- Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. for $16.25 per share, valuing the company at $1.5 billion net of Tempus’ existing ownership stake.
- The transaction integrates Personalis’ ultrasensitive NeXT Personal® tumor-informed minimal residual disease (MRD) liquid biopsy test into Tempus’ AI-enabled multimodal clinical data engine.
- Addresses a total addressable market estimated at $20 billion, serving an expected 2.1 million newly diagnosed U.S. cancer patients requiring long-term, longitudinal disease monitoring.
- Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests during the quarter—a 33% sequential volume increase quarter-over-quarter.
- The deal is structured primarily as a stock transaction (with up to 50% cash option) and is expected to close in late 2026 or early 2027 following shareholder and regulatory approvals.
Ultrasensitive ctDNA Detection and Multimodal AI Fusion
The combination of Tempus’ AI platform and Personalis’ whole-genome, tumor-informed sequencing creates an integrated molecular intelligence engine across biopharma R&D and clinical care:
- Industry-Leading Sensitivity: Personalis’ NeXT Personal® platform utilizes whole-genome sequencing to map a patient’s unique tumor signature, allowing detection of ctDNA down to single-digit parts per million (PPM).
- Medicare Reimbursement Expansion: The NeXT Personal test already holds Medicare reimbursement coverage across three clinical indications, with additional coverage expansion actively underway.
- Multimodal AI Integration: Fuses longitudinal blood-based liquid biopsy results with Tempus’ massive library of clinical records, pathology imaging, and real-world outcomes data to fuel predictive biomarker discovery.
- High-Volume Growth Trajectory: Personalis demonstrated strong commercial momentum ahead of the acquisition, delivering 10,384 clinical tests in Q2—a 33% quarter-over-quarter volume expansion yielding $22.4 million in preliminary quarterly revenue.
“MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs,” stated Eric Lefkofsky, CEO of Tempus. “Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity.”
